Anxiety Disorders And Depression Therapeutic Drug Market Growth, Trends and Forecast by 2031

MARKET INTRODUCTION

Depression and anxiety disorders are one of the most common psychiatric disorders affecting a vast population worldwide. Depression; is related to a state of emotion that further affects actions, thoughts, and sometimes the sleeping pattern of the concerned person. Depression is the most common type of mental disorder affecting nearly 350 million patients of varied scale age groups, whereas anxiety is a stress reaction. An extreme level of pressure results in anxiety disorders, which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder. Anxiety disorders include obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder (PTSD), and phobias. Anxiety disorders are the most prevalent psychiatric disorders and are associated with a high burden of illness.

MARKET DYNAMICS

The anxiety disorders and depression therapeutic drug market has shown a significant evolution over the forecast period. The rise of anxiety disorders and depression is driven by the rising geriatric population which majorly drives the therapeutic drug market, reduced side effects, and greater efficacy of new/innovative drugs along with the accelerating prevalence of anxiety & depression disorders. As per data by the World Health Organization in 2012, depressive disorder affected 350 million people globally, which is expected to increase due to the upward trend in adopting sedentary lifestyles. Depression is the second-leading cause of disabilities globally, raising the need to develop innovative medications shortly. Furthermore, the presence of favorable reimbursement policies in developed countries for medications and therapies coupled with their high success rates are anticipated to drive the growth over the forecast period. However, patent expiration of most drugs combined with the increasing rate of drug withdrawals and the introduction of generic variants on a large scale is expected to restrain the growth of the anxiety disorders and depression therapeutic drug market.

MARKET SCOPE

The "Anxiety Disorders and Depression Therapeutic Drug Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry's pharmaceuticals, focusing on the global market trend analysis. This report outlines the anxiety disorders and depression therapeutic drug market with detailed market segmentation by drug class, treatment indication, and end-user. The anxiety disorders and depression therapeutic drug market is estimated to witness a high rise during the forecast period. It focuses on the vital statistics on the leading players' market status in the anxiety disorders and depression therapeutic drug market and provides key opportunities and trends in the market.

MARKET SEGMENTATION

The market is categorized based on the drug class, treatment indication, and end user. Based on the drug class, the market is segmented as SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors),TCAs (Tricyclic Antidepressants), buspirone, and others. Based on the treatment indication, the segmentation of the market is into OCD (Obsessive Compulsive Disorder), phobias, panic disorders, others. Based on end user, the segmentation of the market is into hospitals, mental healthcare centers, asylums, and others.

REGIONAL FRAMEWORK

The report states a detailed outline of the industry, consisting of both quantitative and qualitative information. It offers a sketch and forecast of the anxiety disorders and depression therapeutic drug market based on various segments. The report also consists of market size and forecast estimates from the year 2021 to2031with respect to five main regions, namely; North America, Asia-Pacific (APAC), Europe, Middle East, and Africa (MEA), and South & Central America (SCAM). The anxiety disorders and depression therapeutic drug market by each region is then sub-segmented into respective countries and segments. It comprises the analysis and forecast of 18 countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the anxiety disorders and depression therapeutic drug market from both the demand and supply sides. Furthermore, it evaluates market dynamics regarding the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. It also consists of precise PEST analysis for all five regions, namely, North America, Asia Pacific, Europe, Middle East, and Africa, and South & Central America, after assessing political, social, economic, and technological factors affecting the Anxiety disorders and depression therapeutic drug market in these regions.

MARKET PLAYERS

The report contains critical developments in the anxiety disorders and depression therapeutic drug market as inorganic and organic growth strategies. Several companies are pivoting on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed were collaborations and acquisitions &partnerships. Various such activities have paved the path for elaborating the business and customer base of market players. The market players from the anxiety disorders and depression therapeutic drug market are estimated to have profitable growth opportunities in the coming years with the higher demand for anxiety disorders and depression therapeutic drugs in the global market. Given below is the list of a few companies engaged in the anxiety disorders and depression therapeutic drug market.
The report also offers key players' profiles in the anxiety disorders and depression therapeutic drug market, along with their SWOT analysis and market strategies. Also, the report focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided, critical development in the past five years.
- GlaxoSmithKline plc.
- Eli Lilly and Company.
- Forest Laboratories, Inc.
- AstraZeneca
- sanofi-aventis U.S. LLC
- Merck & Co., Inc.
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- H. Lundbeck A/S
The Insight Partner's dedicated research and the analytical team comprises of experienced professionals with advanced statistical expertise and offers several customization options in the current report.

Anxiety Disorders And Depression Therapeutic Drug Report Scope